Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Inclusion Criteria:

• Willing to provide informed consent.

• Willing to comply with all study procedures and be available for the duration of thestudy.

• Documented diagnosis of at least one CDI within the last 180 days with treatmentcompleted.

• Currently receiving systemic antibiotics for a non-CDI condition with anticipatedduration of no more than 2 weeks.

• Females of childbearing potential must have a negative pregnancy test prior torandomization and agree to use adequate contraception prior to randomization, forthe duration of the study, and for 4 weeks following study completion.

• Have received no more than 72 hours of non-CDI antibiotics.

Exclusion Criteria:

• History of hypersensitivity or allergy to oral vancomycin.

• Current use of oral vancomycin

• Patients on concurrent treatment with metronidazole or tetracycline monotherapy forany indication

• Patients diagnosed with inflammatory bowel disorder (Crohn's disease), or bacterialgastrointestinal infection cause by agents other than C. difficile (e.g. Salmonellasp.), toxic megacolon and/or known small bowel ileus.

• Dysphagia (inability to swallow capsules) or unwilling to swallow capsules.

• Major gastrointestinal surgery within 3 months of enrollment (does not includeappendectomy or cholecystectomy).

• Any history of total colectomy or bariatric surgery.

• Unable or unwilling to fulfill study requirements.

• Expected life expectancy < 6 months.

• Patients enrolled in another clinical trial with investigational drugs within 30days prior to randomization.

• Women who are pregnant or breast-feeding.

• Any patient deemed not suitable for study participation at the discretion of thestudy investigator.

• Diarrhea (3 or more loose stools in a 24 hour period) at enrollment.